Cargando…
Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition?
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113101/ https://www.ncbi.nlm.nih.gov/pubmed/37082695 http://dx.doi.org/10.21037/atm-23-41 |
| _version_ | 1785027755775098880 |
|---|---|
| author | Van Baelen, Karen Desmedt, Christine Wildiers, Hans Neven, Patrick |
| author_facet | Van Baelen, Karen Desmedt, Christine Wildiers, Hans Neven, Patrick |
| author_sort | Van Baelen, Karen |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10113101 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | AME Publishing Company |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101131012023-04-19 Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? Van Baelen, Karen Desmedt, Christine Wildiers, Hans Neven, Patrick Ann Transl Med Editorial Commentary AME Publishing Company 2023-02-28 2023-03-31 /pmc/articles/PMC10113101/ /pubmed/37082695 http://dx.doi.org/10.21037/atm-23-41 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
| spellingShingle | Editorial Commentary Van Baelen, Karen Desmedt, Christine Wildiers, Hans Neven, Patrick Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? |
| title | Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? |
| title_full | Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? |
| title_fullStr | Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? |
| title_full_unstemmed | Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? |
| title_short | Can ADCs broaden the treatment landscape of metastatic ER+/HER2− breast cancer resistant to CDK4/6 inhibition? |
| title_sort | can adcs broaden the treatment landscape of metastatic er+/her2− breast cancer resistant to cdk4/6 inhibition? |
| topic | Editorial Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10113101/ https://www.ncbi.nlm.nih.gov/pubmed/37082695 http://dx.doi.org/10.21037/atm-23-41 |
| work_keys_str_mv | AT vanbaelenkaren canadcsbroadenthetreatmentlandscapeofmetastaticerher2breastcancerresistanttocdk46inhibition AT desmedtchristine canadcsbroadenthetreatmentlandscapeofmetastaticerher2breastcancerresistanttocdk46inhibition AT wildiershans canadcsbroadenthetreatmentlandscapeofmetastaticerher2breastcancerresistanttocdk46inhibition AT nevenpatrick canadcsbroadenthetreatmentlandscapeofmetastaticerher2breastcancerresistanttocdk46inhibition |